help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on June 5, 2003
Endocrinology, doi:10.1210/en.2003-0139
A more recent version of this article appeared on September 1, 2003
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
144/9/4008    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mesotten, D.
Right arrow Articles by Delhanty, P. J.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mesotten, D.
Right arrow Articles by Delhanty, P. J.D.

Submitted on January 28, 2003
Accepted on May 29, 2003

Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis

Dieter Mesotten1*, Greet Van den Berghe1, Christopher Liddle1, Sally Coulter1, Fiona McDougall1, Robert C. Baxter1, and Patric J.D. Delhanty1

1 Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital,; St Leonards, Australia. Department of Intensive Care Medicine, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium. Department of Clinical Pharmacology, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, Australia.

* To whom correspondence should be addressed. E-mail: dieter.mesotten{at}med.kuleuven.ac.be.

Treatment with high dose human growth hormone (GH), although an effective anabolic agent, has been associated with increased incidence of sepsis, inflammation, multiple organ failure and death in critically ill patients. We hypothesized that GH might increase mortality by exacerbating cholestasis, through modulation of bile acid transporter expression. High dose GH was continuously infused over four days into rats and on the final day LPS was injected. Hepatic bile acid transporter expression was measured by Northern analysis and immunoblotting, and compared with serum markers of cholestasis and endotoxinemia. Compared with non-GH treated controls, GH increased endotoxin-induced markers of cholestasis and liver damage, and augmented IL-6 induction. In endotoxinemia, GH treatment significantly induced Mrp1 mRNA and protein and suppressed Oatp1 and Oatp4 mRNA, suggesting impaired uptake of bilirubin and bile acids at the basolateral surface of the hepatocyte, which could contribute to the observed worsening of cholestasis by GH. This study of endotoxinemia may thus provide a mechanistic link between GH treatment and exacerbation of cholestasis through modulation of basolateral bile acid transporter expression in the rat hepatocyte.


Key words: bilirubin • bile acids and salts • ABC transporters • cytochrome P-450 • critical illness




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. Wood, M. Ananthanarayanan, B. Jones, R. Wooton-Kee, T. Hoffman, F. J. Suchy, and M. Vore
Hormonal Regulation of Hepatic Organic Anion Transporting Polypeptides
Mol. Pharmacol., July 1, 2005; 68(1): 218 - 225.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society